Editas Medicine, an upstart hoping to treat patients by correcting their genes, went public yesterday. But the company already faces several concerns---most pressingly, a patent battle.
The post Crispr Gene-Editing Upstart Editas Goes Public as Patent Battle Rages appeared first on WIRED.